<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421432</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2015-0050</org_study_id>
    <nct_id>NCT02421432</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and the Efficacy of Transanal TME in Difficult Cases</brief_title>
  <official_title>A Pilot Study for the Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision in Difficult Cases of Laparoscopic Surgery for Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluation of the safety and the efficacy of transanal total&#xD;
      mesorectal excision in difficult case.&#xD;
&#xD;
      Difficult case is defined as below;&#xD;
&#xD;
      - If any one of the following (1 or 2 or 3)&#xD;
&#xD;
        1. BMI: 30 or more&#xD;
&#xD;
        2. Tumor size: more than 7cm in long diameter&#xD;
&#xD;
        3. CRM: mesorectal fascia involvement or less than 1 mm on MRI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will have their rectal cancer removed using a technique combining surgery through&#xD;
      the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the&#xD;
      end of the procedure, the rectum will be removed though the anus or ileostomy formation site,&#xD;
      the bowel will be re-connected to the anus, and a temporary diverting stoma will be created,&#xD;
      which is standard of care following surgery for this type of cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TME quality &amp; circumferential resection margin (CRM)</measure>
    <time_frame>the day of surgery</time_frame>
    <description>The quality of the mesorectum was determined using pathology reports and scored using three grades:&#xD;
Complete: intact mesorectum with only minor irregularities of a smooth mesorectal surface. No defect is deeper than 5 mm, and there is no coning toward the distal margin of the specimen. There is a smooth circumferential resection margin on slicing.&#xD;
Nearly complete: moderate bulk to the mesorectum, but irregularity of the mesorectal surface. Moderate coning of the specimen is allowed. At no site is the muscularis propria visible, with the exception of the insertion of the levator muscles.&#xD;
Incomplete: little bulk to mesorectum with defects down onto muscularis propria and/or very irregular circumferential resection margin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day postoperative complications</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>The Clavien-Dindo Classification of Surgical Complications. Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions.&#xD;
Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications.&#xD;
Grade III: : Requiring surgical, endoscopic or radiological intervention. Grade IV: Life-threatening complication (including CNS complications)â€¡ requiring IC/ICU-management.&#xD;
Grade V: Death of a patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of harvested Lymph Nodes</measure>
    <time_frame>the day of surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>2-year local recurrence free survival</measure>
    <time_frame>2 years after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 years after surgery</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Transanal total mesorectal excision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopy-assisted transanal total mesorectal excision</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transanal total mesorectal excision</intervention_name>
    <description>Laparoscopy-assisted transanal total mesorectal excision</description>
    <arm_group_label>Transanal total mesorectal excision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age: 20-80 years&#xD;
&#xD;
          -  biopsy-proven adenocarcinoma of the rectum&#xD;
&#xD;
          -  clinical staging (c or yc): T0-3, N0-2, M0&#xD;
&#xD;
          -  Rectal cancer located 3-12 cm from the anal verge&#xD;
&#xD;
          -  ECOG performance status: 2 or less&#xD;
&#xD;
          -  If any one of the following (1 or 2 or 3)&#xD;
&#xD;
               1. BMI: 30 or more&#xD;
&#xD;
               2. Tumor size: more than 7cm in long diameter&#xD;
&#xD;
               3. CRM: mesorectal fascia involvement or less than 1 mm on MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Synchronous colon cancer or other malignancy&#xD;
&#xD;
          -  Obstructing rectal cancer&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Receiving any other study agents&#xD;
&#xD;
          -  Fecal incontinence&#xD;
&#xD;
          -  History of prior colorectal cancer or inflammatory bowel disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Kyung Sohn, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea: National Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 5, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Dae Kyung Sohn</investigator_full_name>
    <investigator_title>MD., PHD.</investigator_title>
  </responsible_party>
  <keyword>trananal TME</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>difficult cases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

